Hypidone hydrochloride(YL-0919)ameliorates functional deficits after traumatic brain injury in mice by activating the sigma-1 receptor for antioxidation

Traumatic brain injury involves complex pathophysiological mechanisms,among which oxidative stress significantly contributes to the occurrence of secondary injury.In this study,we evaluated hypidone hydrochloride(YL-0919),a self-developed antidepressant with selective sigma-1 receptor agonist properties,and its associated mechanisms and targets in traumatic brain injury.Behavioral experiments to assess functional deficits were followed by assessment of neuronal damage through histological analyses and examination of blood-brain barrier permeability and brain edema.Next,we investigated the antioxidative effects of YL-0919 by assessing the levels of traditional markers of oxidative stress in vivo in mice and in vitro in HT22 cells.Finally,the targeted action of YL-0919 was verified by employing a sigma-1 receptor antagonist(BD-1047).Our findings demonstrated that YL-0919 markedly improved deficits in motor function and spatial cognition on day 3 post traumatic brain injury,while also decreasing neuronal mortality and reversing blood-brain barrier disruption and brain edema.Furthermore,YL-0919 effectively combated oxidative stress both in vivo and in vitro.The protective effects of YL-0919 were partially inhibited by BD-1047.These results indicated that YL-0919 relieved impairments in motor and spatial cognition by restraining oxidative stress,a neuroprotective effect that was partially reversed by the sigma-1 receptor antagonist BD-1047.YL-0919 may have potential as a new treatment for traumatic brain injury.

P2Y1 receptor in Alzheimer’s disease

Alzheimer’s disease is the most frequent form of dementia characterized by the deposition of amyloid-beta plaques and neurofibrillary tangles consisting of hyperphosphorylated tau.Targeting amyloid-beta plaques has been a primary direction for developing Alzheimer’s disease treatments in the last decades.However,existing drugs targeting amyloid-beta plaques have not fully yielded the expected results in the clinic,necessitating the exploration of alternative therapeutic strategies.Increasing evidence unravels that astrocyte morphology and function alter in the brain of Alzheimer’s disease patients,with dysregulated astrocytic purinergic receptors,particularly the P2Y1 receptor,all of which constitute the pathophysiology of Alzheimer’s disease.These receptors are not only crucial for maintaining normal astrocyte function but are also highly implicated in neuroinflammation in Alzheimer’s disease.This review delves into recent insights into the association between P2Y1 receptor and Alzheimer’s disease to underscore the potential neuroprotective role of P2Y1 receptor in Alzheimer’s disease by mitigating neuroinflammation,thus offering promising avenues for developing drugs for Alzheimer’s disease and potentially contributing to the development of more effective treatments.

EFFECT OF rhTGF-β1 AND rhGM-CSF ON RECEPTOR EXPRESSIONS IN J6-1 AND J6-2 LEUKEMIC CELLS

ABC immunoperoxidase was used to test the effects of rhTGF-β1 and rhGM-CSF on receptor expressions in J6-1 and J6-2 leukemic cell lines. Computer assisted image analysis system was introduced to evaluate positive index of time-and dose-dependent specimens. The expression of c-kit was elevated both in positive rate and positive index by TGF-01 in both time- and dose-dependent manners. Ing/ml rhTGF-β1 simultaneously enhanced the expression of c-fms and PDGF-R which is not detected in 50 ng / ml GM-CSF treatment. Endoglin was down-regulated after TGF-β treatment and up-regulated in J6-2 cells after GM-CSF treatment, c-kit Expression was elevated by TGF-β in J6-1 cells while decreased by both in J6-2 cells.

黄鳝csf1r基因的克隆及时空表达特征分析

【目的】克隆黄鳝csf1r基因,并对其时空表达特性进行分析,为探明csf1r基因在黄鳝不同体色形成中的作用奠定基础。【方法】采用RACEs(Rapid-amplification of cDNA ends)技术从黄鳝皮肤cDNAs中克隆得到csf1r基因的全长cDNA序列,对其编码蛋白进行生物信息学分析。采用实时荧光定量PCR(qRT-PCR)方法检测csf1r基因在黄鳝不同组织、不同发育时期胚胎或个体及3种体色黄鳝(黄黑斑鳝、碎花斑鳝和隐花斑鳝)皮肤和肾脏中的相对表达量,分析该基因的表达特征。测定3种体色黄鳝肝脏中的碱性磷酸酶(AKP)、超氧化物歧化酶(SOD)活性和总抗氧化能力(T-AOC)。【结果】黄鳝csf1r cDNA序列全长为4430 bp(GenBank收录号:OP589303),其编码区长度为2937 bp,编码978个氨基酸,存在免疫球蛋白结构域和蛋白激酶催化结构域2个保守结构域。荧光定量PCR结果表明,csf1r基因在黄鳝脑、精巢、卵巢、肠、心脏、肾脏、肝脏、肌肉、皮肤和脾脏等组织中均有表达,在脾脏和心脏中表达量较高,其次是肾脏、皮肤和肌肉,卵巢中表达量最低;csf1r在胚胎眼晶体形成期开始大量表达,显微观察发现该时期胚胎的躯干上开始有色素颗粒出现。在3种体色黄鳝皮肤和肾脏中,csf1r基因在黄黑斑鳝的皮肤中表达量最低,而在其肾脏中表达量最高。3种体色黄鳝肝脏氧化应激指标测定结果发现,黄黑斑鳝肝脏中的碱性磷酸酶(AKP)、超氧化物歧化酶(SOD)活性和总抗氧化能力比其他2种体色黄鳝高,但是差异未达显著水平。【结论】csf1r基因可能不仅参与了黄鳝体色的形成,还与黄鳝非特异性免疫相关。

Identification of transient receptor potential channel genes and functional characterization of TRPA1 in Spodoptera frugiperda

Spodoptera frugiperda is a highly destructive pest that has become a global problem due to its robust reproductive and migratory capabilities.Transient receptor potential(TRP)channels,which constitute a vast ion channel family,play pivotal roles in sensing the external environment and maintaining internal homeostasis in insects.TRP channels have been widely investigated for their critical roles in regulating various insect behaviors in recent years.In this study,we identified 15 TRP gene loci encoding 26 transcripts in the genome of S.frugiperda and analyzed their expression profiles at different developmental stages.The results revealed that S.frugiperda possesses four TRPC genes,six TRPA genes,one TRPM gene,two TRPV genes,one TRPN gene,and one TRPML gene,while a canonical TRPP is absent.Moreover,the SfruTRPA1 was functionally characterized using the Xenopus oocyte expression system.The results showed that SfruTRPA1 is activated by temperature increases from 20 to 45℃,and there is no significant desensitization after repeated stimuli within the same temperature range.Additionally,SfruTRPA1 is activated by certain natural chemicals,including allyl isothiocyanate(AITC)and cinnamaldehyde(CA).These findings provide valuable insights to the TRP genes in S.frugiperda.

Glucagon-like peptide-1 receptor agonists as a possible intervention to delay the onset of type 1 diabetes:A new horizon

Type 1 diabetes(T1D)is a chronic autoimmune condition that destroys insulinproducing beta cells in the pancreas,leading to insulin deficiency and hyperglycemia.The management of T1D primarily focuses on exogenous insulin replacement to control blood glucose levels.However,this approach does not address the underlying autoimmune process or prevent the progressive loss of beta cells.Recent research has explored the potential of glucagon-like peptide-1 receptor agonists(GLP-1RAs)as a novel intervention to modify the disease course and delay the onset of T1D.GLP-1RAs are medications initially developed for treating type 2 diabetes.They exert their effects by enhancing glucose-dependent insulin secretion,suppressing glucagon secretion,and slowing gastric emptying.Emerging evidence suggests that GLP-1RAs may also benefit the treatment of newly diagnosed patients with T1D.This article aims to highlight the potential of GLP-1RAs as an intervention to delay the onset of T1D,possibly through their potential immunomodulatory and anti-inflammatory effects and preservation of beta-cells.This article aims to explore the potential of shifting the paradigm of T1D management from reactive insulin replacement to proactive disease modification,which should open new avenues for preventing and treating T1D,improving the quality of life and long-term outcomes for individuals at risk of T1D.

血清VEGF、G-CSF、sTREM-1与急性心肌梗死患者PCI术后支架内再狭窄的相关性研究

目的探讨血清血管内皮生长因子(VEGF)、粒细胞集落刺激因子(G-CSF)、可溶性髓系细胞触发受体-1(sTREM-1)与急性心肌梗死(AMI)患者经皮冠状动脉介入治疗(PCI)术后支架内再狭窄(ISR)的关系。方法选取商丘市第一人民医院2020年2月—2021年3月行PCI术治疗且完成随访的100例AMI患者为研究对象,根据PCI术后12个月造影复查结果分为ISR组(n=24,支架内狭窄程度≥50%)和非ISR组(n=76,支架内狭窄程度<50%)。比较两组一般临床资料、术后1 d及7 d血清VEGF、G-CSF、sTREM-1水平,Logisitc回归分析影响ISR发生的危险因素,以及各指标不同水平对发生ISR的危险度。结果ISR组糖尿病率、冠状动脉多支病变率较非ISR组高(P<0.05);ISR组术后1 d、7 d血清VEGF、G-CSF较非ISR组低,sTREM-1水平较非ISR组高(P<0.05);Logistic回归分析显示,糖尿病、冠状动脉病变支数、术后1 d及7 d血清VEGF、G-CSF、sTREM-1水平均是影响AMI患者PCI术后发生ISR的因素(P<0.05);术后1 d、7 d,血清VEGF、G-CSF、sTREM-1高水平患者发生ISR的危险度均较低水平者高。结论监测AMI患者PCI术后血清VEGF、G-CSF、sTREM-1表达水平对预测ISR发生具有一定价值。

Molecular cloning, pathologically-correlated expression and functional characterization of the colony- stimulating factor 1 receptor （CSF-1R） gene from a teleost, Plecoglossus altivelis

Colony-stimulating factor 1 receptor （CSF-1R） is an important regulator of monocytes/macrophages （MO/MФ）. Although several CSF-1R genes have been identified in teleosts, the precise role of CSF- 1R in ayu （Plecoglossus altivelis） remains unclear. In this study, we characterized the CSF-1R homologue from P. altivelis, and named it PaCSF-1R. Multiple sequence alignment and phylogenetic tree analysis showed that PaCSF-1R was most closely related to that of Japanese ricefish （Oryzias latipes）. Tissue distribution and expression analysis showed that the PaCSF-1R transcript was mainly expressed in the head kidney-derived MO/MФ, spleen, and head kidney, and its expression was significantly altered in various tissues upon Vibrio anguillarum infection. After PaCSF-1R neutralization for 48 h, the phagocytic activity of MO/MФ was significantly decreased, suggesting that PaCSF-1R plays a role in regulating the phagocytic function of ayu MO/M（P.

CSF1R基因突变致ALSP发病研究进展

成人发病的白质脑病合并轴索球样变和色素性胶质细胞(adult-onset leukoencephalopathy with axonal spheroids and pigmented glia,ALSP)是临床罕见的常染色体显性遗传病,其具体的发病机制目前还未明确。集落刺激因子1受体(colony-stimulating factor 1 receptor,CSF1R)是一种细胞表面跨膜酪氨酸激酶受体,与其相关的编码基因突变已被证实是ALSP的潜在致病因素。然而,目前关于CSF1R基因突变致使ALSP发病的具体机制尚不清楚。本文回顾CSF1R基因在ALSP发病过程中的突变位点及致病机制研究,发现CSF1R突变可以通过显性负性效应、功能丧失、单倍体剂量不足及功能获得等机制导致小胶质细胞功能异常,进而引起ALSP的发病。对ALSP病因的深入认识有助于更好地探索潜在的治疗方法。

Glucagon-like peptide 1 receptor activation:anti-inflammatory effects in the brain

The glucagon-like peptide 1 is a pleiotropic hormone that has potent insulinotropic effects and is key in treating metabolic diseases such as diabetes and obesity.Glucagon-like peptide 1 exerts its effects by activating a membrane receptor identified in many tissues,including diffe rent brain regions.Glucagon-like peptide 1 activates several signaling pathways related to neuroprotection,like the support of cell growth/survival,enhancement promotion of synapse formation,autophagy,and inhibition of the secretion of proinflammatory cytokines,microglial activation,and apoptosis during neural morphogenesis.The glial cells,including astrocytes and microglia,maintain metabolic homeostasis and defe nse against pathogens in the central nervous system.After brain insult,microglia are the first cells to respond,followed by reactive astrocytosis.These activated cells produce proinflammato ry mediators like cytokines or chemokines to react to the insult.Furthermore,under these circumstances,mic roglia can become chro nically inflammatory by losing their homeostatic molecular signature and,consequently,their functions during many diseases.Several processes promote the development of neurological disorders and influence their pathological evolution:like the formation of protein aggregates,the accumulation of abnormally modified cellular constituents,the formation and release by injured neurons or synapses of molecules that can dampen neural function,and,of critical impo rtance,the dysregulation of inflammato ry control mechanisms.The glucagonlike peptide 1 receptor agonist emerges as a critical tool in treating brain-related inflammatory pathologies,restoring brain cell homeostasis under inflammatory conditions,modulating mic roglia activity,and decreasing the inflammato ry response.This review summarizes recent advances linked to the anti-inflammato ry prope rties of glucagon-like peptide 1 receptor activation in the brain related to multiple sclerosis,Alzheimer’s disease,Parkinson’s disease,vascular dementia,or chronic migraine.

Glucagon-like peptide 1 receptor agonist:A potential game changer for cholangiocarcinoma

Glucagon-like peptide-1 receptor(GLP-1R)agonist,a subgroup of incretin-based anti-diabetic therapies,is an emerging medication with benefits in reducing blood glucose and weight and increasing cardiovascular protection.Contrarily,concerns have been raised about GLP-1R agonists increasing the risk of particular cancers.Recently,several epidemiological studies reported contradictory findings of incretin-based therapy on the risk modification for cholangiocarcinoma(CCA).The first cohort study demonstrated that incretin-based therapy was associated with an increased risk of CCA.Later studies,however,showed a null effect of incretinbased therapy on CCA risk for dipeptidyl peptidase-4 inhibitor nor GLP-1R agonist.Mechanistically,glucagon-like peptide 1 receptor is multifunctional,including promoting cell growth.High GLP-1R expressions were associated with progressive phenotypes of CCA cells in vitro.Unexpectedly,the GLP-1R agonist showed anti-tumor effects on CCA cells in vitro and in vivo with unclear mechanisms.Our recent report also showed that GLP-1R agonists suppressed the expression of GLP-1R in CCA cells in vitro and in vivo,leading to the inhibition of CCA tumor growth.This editorial reviews recent evidence,discusses the potential effects of GLP-1R agonists in CCA patients,and proposes underlying mechanisms that would benefit from further basic and clinical investigation.

GLP-1 receptor agonists and myocardial metabolism in atrial fibrillation

Atrial fibrillation(AF)is the most common cardiac arrhythmia.Many medical conditions,including hypertension,diabetes,obesity,sleep apnea,and heart failure(HF),increase the risk for AF.Cardiomyocytes have unique metabolic characteristics to maintain adenosine triphosphate production.Significant changes occur in myocardial metabolism in AF.Glucagon-like peptide-1 receptor agonists(GLP-1RAs)have been used to control blood glucose fluctuations and weight in the treatment of type 2 diabetes mellitus(T2DM)and obesity.GLP-1RAs have also been shown to reduce oxidative stress,inflammation,autonomic nervous system modulation,and mitochondrial function.This article reviews the changes in metabolic characteristics in cardiomyocytes in AF.Although the clinical trial outcomes are unsatisfactory,the findings demonstrate that GLP-1 RAs can improve myocardial metabolism in the presence of various risk factors,lowering the incidence of AF.

The Association between GLP-1 Receptor-Based Agonists and the Incidence of Asthma in Patients with Type 2 Diabetes and/or Obesity:A Meta-Analysis

Objective Recent studies have indicated potential anti-inflammatory effects of glucagon-like peptide-1 receptor agonists(GLP-1RAs)on asthma,which is often comorbid with type 2 diabetes mellitus(T2DM)and obesity.Therefore,we conducted a meta-analysis to assess the association between the administration of glucagon-like peptide-1(GLP-1)receptor-based agonists and the incidence of asthma in patients with T2DM and/or obesity.Methods PubMed,Web of Science,Embase,the Cochrane Central Register of Controlled Trials,and Clinicaltrial.gov were systematically searched from inception to July 2023.Randomized controlled trials(RCTs)of GLP-1 receptor-based agonists(GLP-1RA,GLP-1 based dual and triple receptor agonist)with reports of asthma events were included.Outcomes were computed as risk ratios(RR)using a fixedeffects model.Results Overall,39 RCTs with a total of 85,755 participants were included.Compared to non-GLP-1 receptor-based agonist users,a trend of reduced risk of asthma was observed in patients with T2DM or obesity using GLP-1 receptor-based agonist treatments,although the difference was not statistically significant[RR=0.91,95%confidence interval(CI):0.68 to 1.24].Further Subgroup analyses indicated that the use of light-molecular-weight GLP-1RAs might be associated with a reduced the risk of asthma when compared with non-users(RR=0.65,95%CI:0.43 to 0.99,P=0.043).We also performed sensitivity analyses for participant characteristics,study design,drug structure,duration of action,and drug subtypes.However,no significant associations were observed.Conclusion Compared with non-users,a modest reduction in the incidence of asthma was observed in patients with T2DM or obesity using GLP-1 receptor-based agonist treatments.Further investigations are warranted to assess the association between GLP-1 receptor-based agonists and the risk of asthma.

Practical guide:Glucagon-like peptide-1 and dual glucosedependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists in diabetes mellitus

Practical guide:Glucagon-like peptide-1 and dual glucosedependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists in diabetes mellitus common second-line choice after metformin for treating T2DM.Various considerations can make selecting and switching between different GLP-1 RAs challenging.Our study aims to provide a comprehensive guide for the usage of GLP-1 RAs and dual GIP and GLP-1 RAs for the management of T2DM.

The Sigma-1 Receptor as a Pharmacologic Chaperone: Energetics

Initially thought to be an opioid receptor subtype, Sigma-1 receptors (S1R) are now known to be unique proteins that have chaperone-like properties. As such, they play critical roles in cellular signaling, homeostasis, and cell survival. These roles offer significant insight for understanding homeostasis of normal physiologic processes, and the pathophysiologic consequences of disruption of normal function. Because of the broad nature of chaperone action, S1R agonists and antagonists represent potential drug discovery goals for the pharmacotherapeutic treatment of a variety of disorders that result from dysfunctional proteins. The present study summarizes the S1R as a pharmacologic chaperone crucial for protein folding and cellular homeostasis. Through literature review and thermodynamic analysis, it explores how S1R stabilizes target proteins, influencing neuroprotection and potential drug therapies. The binding of chaperones to target proteins is thermodynamically favorable, offering insights into treating diseases linked to protein misfolding.

靶向成纤维细胞生长因子受体1信号改善类风湿关节炎的骨破坏

背景:尽管科研人员已注意到成纤维细胞生长因子受体1在类风湿关节炎骨破坏中展现出巨大潜力,但尚未有学者对成纤维细胞生长因子受体1在类风湿关节炎骨破坏中的研究进展作全面综述。目的:通过查阅国内外相关文献,综合分析成纤维细胞生长因子受体1在类风湿关节炎骨破坏中的机制。方法:以“成纤维细胞生长因子受体1,类风湿关节炎,骨破坏,骨细胞,成骨细胞,破骨细胞,软骨细胞,巨噬细胞,滑膜成纤维细胞,T细胞,血管内皮细胞”为检索词检索中国知网数据库,以“fibroblast growth factor receptor 1,rheumatoid arthritis,bone destruction,osteocytes,osteoblasts,osteoclasts,chondrocytes,macrophages,synovial fibroblasts,T cells,endothelial cells”为检索词检索PubMed数据库,检索时间范围重点为1992年4月至2024年1月。通过阅读文献题目、摘要及全文,根据纳入与排除标准进行筛选,最后纳入82篇文献进行综述。结果与结论:成纤维细胞生长因子受体1广泛表达于骨组织相关细胞,包括骨细胞、成骨细胞、破骨细胞等,可以通过调控这些细胞的功能来影响骨重塑过程和维持骨稳态,促进类风湿关节炎骨破坏的发生和发展。成纤维细胞生长因子受体1还可以在滑膜成纤维细胞和巨噬细胞中参与炎症反应,在内皮细胞中调控滑膜血管生成,从多个方面促进骨破坏。成纤维细胞生长因子受体1可能是类风湿关节炎骨破坏的一个重要参与因素,为进一步研究类风湿关节炎治疗靶点提供依据。

高糖环境中程序性细胞死亡受体1抑制大鼠骨髓间充质干细胞的成骨分化

背景:程序性细胞死亡受体1(programmed death receptor-1,PD-1)在高糖环境下影响骨髓间充质干细胞成骨分化的作用机制尚不清楚。目的:探讨高糖环境中PD-1对大鼠骨髓间充质干细胞成骨分化的影响及其调控机制。方法:将大鼠骨髓间充质干细胞随机分为正常糖组(5.6 mmol/L)、高糖组(30 mmol/L)、PD-1过表达组、PD-1过表达空载组、PD-1敲低组、PD-1敲低空载组、PI3K/AKT通路抑制剂组(PD-1敲低+5μmol/L LY294002)。通过在高糖培养基中培养大鼠骨髓间充质干细胞来模拟体外糖尿病环境,采用qRT-PCR检测大鼠骨髓间充质干细胞中PD-1及其配体PD-L1和成骨标志物Runx2、OSX的mRNA表达,采用碱性磷酸酶染色和茜素红S染色观察成骨分化能力,采用CCK-8检测细胞增殖情况,采用Western blot检测PD-1、PD-L1、p-PI3K、p-AKT的蛋白表达。结果与结论:①高糖组PD-1及PD-L1表达显著高于正常糖组,高糖组骨髓间充质干细胞的成骨分化能力较正常糖组显著下降;②敲低PD-1表达可以促进骨髓间充质干细胞的成骨分化、增加细胞增殖活性,同时激活PI3K/AKT通路;③加入PI3K/AKT通路抑制剂LY294002后,骨髓间充质干细胞成骨分化能力显著下降。结果表明:PD-1依赖于PI3K/AKT信号通路抑制高糖环境下大鼠骨髓间充质干细胞的成骨分化。

Receptor tyrosine kinase-like orphan receptor 1:A novel antitumor target in gastrointestinal cancers

Receptor tyrosine kinase-like orphan receptor 1(ROR1)is a member of the type I receptor tyrosine kinase family.ROR1 is pivotal in embryonic development and cancer,and serves as a biomarker and therapeutic target.It has soluble and membrane-bound subtypes,with the latter highly expressed in tumors.ROR1 is conserved throughout evolution and may play a role in the development of gastrointestinal cancer through multiple signaling pathways and molecular mechanisms.Studies suggest that overexpression of ROR1 may increase tumor invasiveness and metastasis.Additionally,ROR1 may regulate the cell cycle,stem cell characteristics,and interact with other signaling pathways to affect cancer progression.This review explores the structure,expression and role of ROR1 in the development of gastrointestinal cancers.It discusses current antitumor strategies,outlining challenges and prospects for treatment.

成纤维细胞生长因子受体1 抑制剂对胶原诱导关节炎模型大鼠骨破坏的影响

背景:课题组前期的研究表明靶向成纤维细胞生长因子受体1(fibroblast growth factor receptor 1,FGFR1)可能是治疗类风湿性关节炎的有效靶点。目的:探讨FGFR1抑制剂(PD173074)对胶原诱导关节炎模型大鼠骨破坏的影响。方法:将25只雌性SD大鼠随机分为5组,正常对照组、模型组、甲氨蝶呤组、PD173074低剂量组、PD173074高剂量组。除正常对照组外,其余各组大鼠建立Ⅱ型胶原诱导关节炎模型。造模成功后正常组及模型组大鼠腹腔注射无菌PBS,甲氨蝶呤组药物注射剂量为1.04 mg/kg,PD173074低剂量组和高剂量组药物注射剂量分别为5,20 mg/kg,1次/周。给药4周后取材,观察大鼠临床症状以及关节肿胀情况,踝关节Micro-CT三维重建及分析,观察踝关节病理变化,检测关节周围血管生成情况及核因子κB受体活化因子配体的表达,检测关节滑膜中p-FGFR1、血管内皮生长因子A、抗酒石酸酸性磷酸酶的表达,观察肝、脾、肾病理变化并计算肝、脾、肾指数。结果与结论:①PD173074能够减轻模型大鼠踝关节临床症状及关节肿胀,延缓骨质丢失,改善骨结构,减轻关节滑膜侵袭以及软骨骨侵蚀,降低关节周围破骨细胞数量,抑制关节滑膜组织中的血管生成,降低核因子κB受体活化因子配体的表达,抑制FGFR1磷酸化蛋白、抗酒石酸酸性磷酸酶和血管内皮生长因子A的蛋白表达。②大鼠肝、脾、肾病理观察表明经过PD173074治疗后无明显的毒副作用。③研究证明了FGFR1抑制剂能够延缓Ⅱ型胶原诱导关节炎模型大鼠关节炎症及骨破坏的进展,并抑制血管的生成。初步验证了PD173074在Ⅱ型胶原诱导关节炎模型中的治疗作用,其可能是通过抑制FGFR1磷酸化发挥作用,为寻找类风湿性关节炎新的治疗靶点提供了方向。

基于Cre/Loxp系统的Csf1r-Cre^(ERT2)R26R^(EYFP)报告基因小鼠的构建及效率检测

目的构建报告基因小鼠,评价Csf1r-Cre^(ERT2)介导增强黄色荧光素蛋白EYFP标记组织CD45^(+)细胞CSF1R的效率。方法Csf1r-Cre^(ERT2)小鼠与R26R^(EYFP)小鼠繁育,他莫昔芬诱导、PCR筛选Csf1r-Cre^(ERT2)R26R^(EYFP)小鼠,流式细胞术和Western blot分析EYFP对不同组织以及不同组织CD45^(+)细胞中CSF1R的标记效率。结果获得Csf1r-Cre^(ERT2)R26R^(EYFP)报告基因小鼠。此外,Csf1r-Cre^(ERT2)小鼠介导EYFP可有效标记小鼠组织CSF1R以及不同部位中CD45^(+)细胞。与R26R^(EYFP)组比较,Csf1r-Cre^(ERT2)小鼠介导EYFP标记效率最高的是脑组织(P<0.001),最低的是胸腺组织(P<0.05),脾脏组织则差异无统计学意义。结论成年Csf1r-Cre^(ERT2)小鼠与R26R^(EYFP)小鼠是获得Csf1r-Cre^(ERT2)R26R^(EYFP)诱导型条件性荧光小鼠的有效途径。Csf1r-Cre^(ERT2)介导EYFP可对小鼠不同部位CSF1R以及CD45^(+)细胞中CSF1R进行有效示踪。